...
首页> 外文期刊>World Journal of Gastroenterology >A novel HBV antisense RNA gene delivery system targeting hepatocellular carcinoma
【24h】

A novel HBV antisense RNA gene delivery system targeting hepatocellular carcinoma

机译:靶向肝细胞癌的新型HBV反义RNA基因递送系统

获取原文
获取原文并翻译 | 示例
           

摘要

AIM: To construct a novel HBV antisense RNA delivery system targeting hapatocellular carcinoma and study its inhibitory effect in vitro and in vivo. METHODS: GE7,a 16-peptide specific to EGFR, and HA20, a homologue of N-terminus of haemagglutinin of influenza viral envelope protein, were synthesized and conjugated with polylysin. The above conjugates were organized into the pEBAF-as-preS2, a hepatocarcinoma specific HBV antisense expression vector, to construct a novel HBV antisense RNA delivery system, named AFP-enhancing 4-element complex. Hepatocelluar carcinoma HepG2.2.15 cells was used to assay the in vitro inhibition of the complex on HBV. Expression of HBV antigen was assayed by ELISA. BALB/c nude mice bearing HepG2.2.15 cells were injected with AFP-enhancing 4-element complex. The expression of HBV antisense RNA was examined by RT-PCR and the size of tumor in nude mice were measured. RESULTS: The AFP-enhancing 4-element complex was constructed and DNA was completely trapped at the slot with no DNA migration when the ratio of polypeptide to plasmid was 1:1. The expression of HBsAg and HBeAg of HepG2.2.15 cells was greatly decreased after being transfected by AFP-enhancing 4-element complex. The inhibitory rates were 33.4 % and 58.5 % respectively. RT-PCR showed HBV antisense RNA expressed specifically in liver tumor cells of tumor-bearing nude mice. After 4 injections of AFP-enhancing 4-element complex containing 0.2 g DNA, the diameter of the tumor was 0.995 cm+-0.35, which was significantly smaller than that of the control groups (2.215 cm+-0.25, P<0.05). CONCLUSION: AFP-enhancing 4-element complex could deliver HBV antisense RNA targeting on hepatocarcinoma and inhibit both HBV and liver tumor cells in vitro and in vivo.
机译:目的:构建针对肝细胞癌的新型HBV反义RNA递送系统,研究其在体内外的抑制作用。方法:合成EGFR特异的16肽GE7和流感病毒包膜蛋白血凝素N末端的同源物HA20,并与溶血素结合。将上述缀合物组织到肝癌特异性HBV反义表达载体pEBAF-as-preS2中,构建了新型的HBV反义RNA递送系统,称为AFP增强4元件复合物。肝细胞癌HepG2.2.15细胞用于检测复合物对HBV的体外抑制作用。通过ELISA检测HBV抗原的表达。向携带HepG2.2.15细胞的BALB / c裸鼠注射增强AFP的4元素复合物。通过RT-PCR检测HBV反义RNA的表达,并测量裸鼠的肿瘤大小。结果:当多肽与质粒的比例为1:1时,构建了增强AFP的4元素复合物,DNA被完全捕获在槽中,没有DNA迁移。 HepG2.2.15细胞经增强AFP的4元复合物转染后,HBsAg和HBeAg的表达大大降低。抑制率分别为33.4%和58.5%。 RT-PCR显示HBV反义RNA在荷瘤裸鼠的肝肿瘤细胞中特异性表达。在四次注射含有0.2 g DNA的增强AFP的4元素复合物后,肿瘤直径为0.995 cm + -0.35,显着小于对照组(2.215 cm + -0.25,P <0.05)。结论:增强AFP的4元素复合物可在体内外释放针对肝癌的HBV反义RNA,并抑制HBV和肝肿瘤细胞。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号